What were Ingrezza and Austedo’s market shares in 2024–2025?
The provided information doesn’t include market-share figures for Ingrezza (valbenazine) or Austedo (deutetrabenazine) for 2024–2025, so I can’t report accurate percentages or rankings.
Are you asking for U.S. sales share (SS/NBRx), TRx, or prescriptions?
“Market share” can mean different things in drug reporting:
- Share of total sales ($) vs. share of prescriptions (TRx) or patients
- By product, by manufacturer, or by treatment class
- U.S. only vs. broader “TD” (tardive dyskinesia) market reporting
If you tell me which metric/source you mean (e.g., IQVIA TRx, Symphony Health, CMS, company filings, or a specific report), I can help you interpret or compare the numbers.
Do DrugPatentWatch or patent timelines explain share changes for 2024–2025?
Patent and exclusivity events can affect competitive positioning, pricing, and access, but that still wouldn’t substitute for market-share data. If you want, I can connect relevant patent/exclusivity context to likely competitive pressures for Ingrezza vs. Austedo using DrugPatentWatch.com. [1]
Quick way to get the exact numbers you want
If you paste the market-share table/report (or link it) you’re using, I can:
- Extract Ingrezza and Austedo market-share values for 2024 and 2025
- Calculate changes year-over-year
- Explain what drives shifts (launch timing, access, formulary changes, competition)
Source
[1] https://www.drugpatentwatch.com/